查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984158

細胞和基因治療生物製造CDMO市場：按服務類型、治療類型、技術、規模、製程階段、應用和最終用戶分類－2026-2032年全球市場預測

Cell & Gene Therapy Biomanufacturing CDMO Market by Service Type, Therapy Type, Technology, Scale, Process Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞和基因治療的生物生產、開發、製造和生產組織 (CDMO) 的市場價值將達到 266.6 億美元，到 2026 年將成長到 291.7 億美元，到 2032 年將達到 502.1 億美元，複合年成長率為 9.46%。

主要市場統計數據
基準年 2025 266.6億美元
預計年份：2026年 291.7億美元
預測年份 2032 502.1億美元
複合年成長率 (%) 9.46%

相關人員需要明確戰略緊迫性，以協調先進治療方法的大規模生產能力、監管合規性和商業計劃。

生物學與製造技術的融合正在重塑先進治療方法從概念到臨床應用的進程。基因編輯、載體工程和細胞處理領域的最新突破提升了治療潛力，同時也提高了生產製造的技術和監管門檻。隨著研究重點從實驗室規模的創新轉向穩健、可重複的生產，各機構需要重新評估夥伴關係、設施策略和產能投資，以維持臨床生產能力並確保產品品質。

技術、商業和監管變革的結合，迫使 CDMO 和研發公司追求一體化平台策略，以確保永續的競爭優勢。

細胞和基因療法的生物製造環境正經歷著許多複雜的變革，這些變革正在重新定義產品的開發、生產和交付方式。載體設計、非病毒遞送方法和封閉式系統處理的技術進步提高了產品的穩健性並降低了污染風險。同時，分析和製程表徵技術的同步發展使得產品特性的控制更加精細。這些改進促使申辦方和服務供應商將平台的穩健性和工藝的可重複性與簡單的生產能力同等重視。

評估 2025 年美國關稅變化將如何加劇供應鏈風險，並鼓勵先進藥物製造領域採購多元化和策略性回歸國內生產。

影響關稅和貿易的政策決策會對整個先進處理生態系統產生連鎖反應，改變成本、進度和供應商關係。美國近期的一些舉措，例如引入2025年關稅減讓，為複雜全球供應鏈中經常進口的零件、一次性耗材和某些原料帶來了新的貿易摩擦。這迫使各機構重新評估對供應商的依賴程度、定價策略和庫存政策，以維持專案進度和分析處理能力。

詳細的細分分析，按服務類型、技術、治療方法和流程階段區分能力、監管要求和投資重點。

透過細分觀點捕捉細微差異，可以揭示不同服務類型、治療方法、技術選擇、應用、規模、最終用戶和流程階段的需求差異，從而清晰地展現整個生態系統中的機會和風險。對服務類型的檢驗表明，分析服務、臨床生產、商業化生產和製程開發提供者面臨不同的需求促進因素。分析服務越來越需要平台化檢測和可比性方面的專業知識；臨床生產強調快速放大生產規模和CMC（化學、生產和品管）準備；商業化生產需要持續的產能和成本控制；而製程開發在連接藥物發現和可重複生產方面發揮著至關重要的作用。

區域監管成熟度、製造能力和供應鏈趨勢如何重塑全球市場的夥伴關係模式和投資決策？

區域趨勢正以不同的方式影響製造商、贊助商和服務供應商的策略重點。在美洲，成熟的製造生態系統和完善的法規結構支援計畫快速過渡到臨床階段。同時，北美供應鏈和契約製造網路正集中力量於病毒和非病毒平台。這種環境有利於能夠快速擴展規模並滿足嚴格監管要求的夥伴關係，但同時也加劇了對人才和專業技術的競爭。

競爭格局概述，重點介紹規模、專業知識和策略夥伴關係關係如何決定供應商的差異化和長期客戶維繫。

先進治療藥物生產生態系統的競爭格局多元化，涵蓋了傳統的大型合約研發企業（CDMO）、專業的載體和細胞療法服務供應商，以及垂直整合的研發生產公司。成熟的契約製造製造商擁有規模優勢、豐富的監管經驗和全球企業發展，這些優勢對於即將實現商業化供應的專案尤其寶貴。同時，專業服務供應商和新興企業憑藉在特定載體類型、新型遞送方法或客製化製程開發服務方面的深厚技術專長脫穎而出，提供精細化的服務，能夠加速早期專案並降低轉換障礙的風險。

為相關人員提供切實可行的策略措施，以降低先進療法的轉化風險，並建立穩健且擴充性的生產途徑。

領導者必須採取果斷行動，將科學創新與可製造性結合，優先考慮投資和夥伴關係，以保障專案進度和病患用藥。首先，應在專案生命週期的早期階段就協調製程開發和分析，確保將規模化生產考量和產品發布標準納入產品設計決策。這將透過制定清晰的技術轉移藍圖，降低下游風險並縮短合規路徑。

透過結合訪談、技術文獻和監管指導的實用且可重複的研究途徑，檢驗對製造業的營運和策略見解。

這項基於多方面分析的綜合研究，結合一手和二手調查數據，對細胞和基因療法生物製造領域的生產趨勢、運營挑戰和戰略應對措施進行了系統性的闡述。一手資料包括對申辦方和服務供應商機構中負責生產、CMC和法規事務的高級領導進行的結構化訪談，以及與工藝開發科學家和供應鏈經理進行的技術對話，旨在了解運營限制和應對策略。這些定性研究旨在揭示實際決策標準，並闡明臨床開發要求與商業化生產要求之間的差異。

結論是：將製造策略、監管準備和供應鏈韌性聯繫起來，作為先進療法長期成功的核心決定因素。

對技術、營運和策略要素的綜合分析揭示了製造業生態系統正處於轉型之中。科學創新正在加速治療方案的開發，但要確保這些方案得以實現，需要專注於工藝科學、供應鏈韌性和一體化夥伴關係關係。那些能夠協調早期研發階段與可擴展生產方法、分散採購和地理風險、並專注於構建穩健的分析和品管系統的組織，將更有利於保持專案進展勢頭，並在治療方法向更廣泛的臨床應用階段推進時，確保患者能夠獲得治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：細胞與基因治療生物生產CDMO市場：依服務類型分類

  • 分析服務
  • 臨床生產
  • 商業生產
  • 製程開發

第9章：依治療方法分類的細胞和基因治療生物製品生產CDMO市場

  • 細胞療法
    • 同種
    • 自有住房
  • 基因治療

第10章：細胞與基因治療生物生產CDMO市場：依技術分類

  • 非病毒載體
    • 電穿孔
    • 脂質奈米顆粒
  • 病毒載體
    • AAV
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第11章：細胞和基因治療生物製品開發和生產組織（CDMO）的市場規模

  • 臨床量表
  • 商業規模
  • 臨床前規模

第12章：細胞與基因治療生物製造CDMO市場依製程階段分類

  • 下游
  • 上游

第13章：細胞和基因治療生物製品開發和製造組織（CDMO）市場：按應用領域分類

  • 循環系統
  • 神經病學
  • 腫瘤學
  • 罕見疾病

第14章：細胞與基因治療生物生產CDMO市場：依最終用戶分類

  • 生物製藥公司
  • 合約研究機構
  • 研究機構

第15章：細胞與基因治療生物製品CDMO市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：細胞和基因治療生物製品開發和製造組織（CDMO）市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：細胞和基因治療生物製品開發和製造組織的市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國生物細胞和基因治療生產、開發、製造和生產組織（CDMO）市場

第19章：中國細胞與基因治療生物製品開發與製造組織（CDMO）市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics, Inc.
  • Ajinomoto Bio-Pharma Services, Inc.
  • Alvotech A/S
  • BioNTech SE
  • BioReliance
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cobra Biologics Holdings Ltd.
  • Cobra Therapeutics
  • Fujifilm Diosynth Biotechnologies USA, Inc.
  • Genezen Laboratories, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Minaris Regenerative Medicine GmbH
  • Novasep SAS
  • Paragon Bioservices, Inc.
  • Recipharm AB
  • Rentschler Biopharma SE
  • Repligen Corporation
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific, Inc.
  • Thermo Genesis Holdings, Inc.
  • Vironova AB
  • WuXi AppTec Co., Ltd.
Product Code: MRR-5C6F41F5AF94

The Cell & Gene Therapy Biomanufacturing CDMO Market was valued at USD 26.66 billion in 2025 and is projected to grow to USD 29.17 billion in 2026, with a CAGR of 9.46%, reaching USD 50.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.66 billion
Estimated Year [2026] USD 29.17 billion
Forecast Year [2032] USD 50.21 billion
CAGR (%) 9.46%

Framing the strategic urgency for stakeholders to align manufacturing capability, regulatory readiness, and commercial planning for advanced therapies at scale

The intersection of biology and manufacturing is reshaping how advanced therapies move from concept to clinic. Recent breakthroughs in gene editing, vector engineering, and cell processing have elevated therapeutic promise while simultaneously raising the technical and regulatory bar for manufacturing. As attention shifts from lab-scale innovation to robust, reproducible production, organizations must rethink partnerships, facility strategies, and capability investment to sustain clinical throughput and ensure product quality.

These dynamics demand that stakeholders-biopharmaceutical developers, contract manufacturers, investors, and regulators-adopt a strategic lens on capacity, technology fit, and supply chain resiliency. Critical decisions made today about process platforms, vector technologies, and outsourced relationships will determine not only the speed to first-in-human studies but also the ability to scale to broader patient populations. Consequently, executives must balance near-term program needs with long-term platform viability in a landscape where scientific complexity and commercial expectations evolve in parallel.

This summary frames the operational, strategic, and commercial pressures shaping cell and gene therapy biomanufacturing and highlights where targeted action can reduce risk and create value across development and manufacturing lifecycles.

How converging technological, commercial, and regulatory shifts are forcing CDMOs and developers to pursue integrated platform strategies for durable competitive advantage

The biomanufacturing landscape for cell and gene therapies is undergoing several converging shifts that are redefining how products are developed, manufactured, and delivered. Technological progress in vector design, non-viral delivery modalities, and closed-system processing is increasing robustness and reducing contamination risk, while parallel advances in analytics and process characterization are enabling deeper control over product attributes. These improvements are prompting sponsors and service providers to prioritize platform resilience and process reproducibility as much as raw capacity.

Concurrently, commercialization pressures are reshaping business models. The need to de-risk supply and accelerate time to clinic has driven more developers to partner with specialized manufacturing organizations, but those partnerships are evolving beyond transactional capacity provision toward integrated service models that encompass process development, regulatory support, and lifecycle management. This shift is accelerating demand for vertically integrated capabilities that can take a program from vector or cell process definition through clinical and commercial manufacturing under a harmonized quality framework.

Finally, regulatory and reimbursement environments are maturing in many jurisdictions, emphasizing consistent product quality, post-market evidence generation, and supply chain transparency. As a result, successful players are those investing in cross-functional integration-uniting scientific innovation with manufacturing science, regulatory strategy, and commercial planning-to ensure therapies can transition smoothly from proof of concept to sustainable patient access.

Assessing how 2025 tariff shifts in the United States are amplifying supply chain risks, prompting sourcing diversification and strategic onshoring in advanced therapy manufacturing

Policy decisions affecting tariffs and trade can have ripple effects across the advanced therapy ecosystem, altering costs, timelines, and supplier relationships. Recent tariff developments in the United States introduced in 2025 have created new transactional friction for components, single-use consumables, and certain raw materials frequently imported through complex global supply chains. This has led organizations to reassess supplier dependencies, pricing strategies, and inventory policies to preserve program schedules and analytical throughput.

Manufacturers and service providers have responded by diversifying sourcing, qualifying alternate suppliers, and in some cases accelerating onshoring of critical inputs to mitigate exposure. For many stakeholders, the cumulative effect is not just an incremental cost increase but a strategic prompt to re-evaluate the end-to-end supply chain. Decisions about where to locate production capacity or whether to maintain buffer inventories are now being made with an eye toward tariff sensitivity, supplier concentration, and logistical complexity.

Moreover, the policy environment has underscored the value of contractual flexibility and regional redundancy. Sponsors that had pre-existing multi-region supply strategies found it easier to absorb transactional shocks, while those with heavily concentrated supplier networks faced longer lead times to secure alternates. Ultimately, tariff-related pressures are accelerating conversations about supply chain resilience, qualifying secondary sources, and embedding contingency planning into program timelines and vendor selection criteria.

Detailed segmentation analysis that differentiates capability, regulatory needs, and investment priorities across service types, technologies, therapy modalities, and process stages

A nuanced segmentation lens reveals how needs diverge across service types, therapy modalities, technology choices, applications, scales, end users, and process stages, creating distinct opportunity and risk profiles across the ecosystem. When examining service type, providers offering analytical services, clinical manufacturing, commercial manufacturing, and process development are experiencing different demand drivers: analytical services increasingly require platformized assays and comparability expertise, clinical manufacturing focuses on rapid scale-up and CMC readiness, commercial manufacturing demands sustained throughput and cost control, and process development bridges discovery and reproducible manufacturing.

Therapy type further differentiates strategy and operations. Cell therapy and gene therapy programs have divergent material flows and regulatory touchpoints, and within cell therapy, allogeneic models emphasize donor sourcing, banking, and immunogenicity control, while autologous models concentrate on individualized logistics and rapid turnaround. Platform technology influences both cost structure and operational complexity; non-viral vectors such as electroporation and lipid nanoparticles offer alternative manufacturing pathways with distinct analytical packages, whereas viral vector platforms include AAV, adenovirus, lentivirus, and retrovirus-each with specific production, purification, and potency challenges that shape facility design and regulatory dossiers.

Application and therapeutic area impact clinical development and manufacturing priorities. Development for cardiovascular, neurology, oncology, and rare diseases requires tailored potency assays, varying dosing paradigms, and different patient recruitment dynamics that affect batch sizes and release testing strategies. Scale considerations-clinical scale, commercial scale, and preclinical scale-translate directly into capital planning and technology selection, since processes that are fit-for-purpose at one scale may not transition economically to another without significant redevelopment. End users such as biopharmaceutical companies, contract research organizations, and research institutions bring different expectations around service level, documentation, and flexibility, influencing how providers design contracting models and capacity commitments.

Finally, process stage segmentation into upstream and downstream activities highlights where investment and expertise concentrate. Upstream operations drive productivity through cell line or vector production efficiencies, while downstream operations determine purity, yield, and formulation stability. Integrating insights across these segmentation dimensions enables stakeholders to align capabilities, prioritize investments, and select partners that match both program-specific technical needs and broader commercialization objectives.

How regional regulatory maturity, manufacturing capacity, and supply chain dynamics are reshaping partnership models and investment decisions across global markets

Regional dynamics shape strategic priorities for manufacturers, sponsors, and service providers in distinct ways. In the Americas, mature manufacturing ecosystems and established regulatory frameworks support rapid program transitions to clinical operations, while North American supply chains and contract manufacturing networks have concentrated capabilities in both viral and non-viral platforms. This environment favors partnerships that can quickly scale and align with stringent regulatory expectations, but it also intensifies competition for qualified talent and specialized capacity.

Across Europe, the Middle East & Africa, diversity in regulatory approaches and infrastructure maturity creates mixed incentives. European markets emphasize harmonized regulatory alignment and stringent quality systems, while several Middle Eastern and African jurisdictions are in earlier stages of capacity building. These differences encourage cross-border collaborations, distributed manufacturing strategies, and investment in regional centers of excellence that can support local clinical programs and provide redundancy for global operations.

In the Asia-Pacific region, rapid expansion of biotech ecosystems, growing domestic biopharma investment, and evolving regulatory pathways are driving significant capability growth. Local suppliers and CDMOs are increasingly competitive on cost and are investing in technical depth across viral vectors and non-viral modalities. Consequently, many global sponsors are balancing near-term cost considerations with long-term risk management by combining local partnerships for certain activities with established partners in other regions to ensure global regulatory alignment and continuity of supply.

Competitive landscape overview highlighting how scale, specialization, and strategic partnerships determine provider differentiation and long-term client retention

Competitors in the advanced therapy manufacturing ecosystem now span legacy large-scale CDMOs, specialized vector and cell therapy service providers, and vertically integrated developer-manufacturers, creating a diverse competitive landscape. Established contract manufacturers bring scale, regulatory experience, and global footprint, which is particularly valuable for programs approaching commercial supply needs. At the same time, specialized providers and emerging firms differentiate through deep technical expertise in specific vector types, novel delivery modalities, or bespoke process development services, offering high-touch capabilities that can accelerate early-stage programs and de-risk translational hurdles.

Strategic partnerships and M&A activity have been common as organizations seek to close capability gaps and secure capacity. Collaborations between technology licensors, equipment manufacturers, and service providers are enabling faster adoption of automation, single-use technologies, and high-throughput analytics. Additionally, academic spinouts and research institutions continue to be critical sources of innovation, feeding new modalities and process approaches into the commercial supply chain. The competitive imperative is to blend scientific differentiation with operational excellence: firms that can demonstrate reproducible processes, robust quality systems, and flexible capacity will be best positioned to capture long-term customer relationships.

Actionable strategic moves for stakeholders to reduce translational risk and build resilient, scalable manufacturing pathways for advanced therapies

Leaders must act decisively to bridge scientific innovation and manufacturability, prioritizing investments and partnerships that protect program timelines and patient access. First, align process development and analytics early in the program lifecycle to ensure that scale-up considerations and release criteria are embedded into product design decisions. This reduces downstream risk and shortens the path to regulatory readiness by creating a clear technical transfer roadmap.

Second, diversify supplier and component sourcing by qualifying secondary suppliers and exploring regional alternatives for critical consumables. Embedding contingency planning into contracts and procurement strategies minimizes disruption from trade policy shifts or single-source failures. Third, invest in platform technologies and automation that increase reproducibility while lowering per-batch variability; standardized unit operations and modular facility designs can accelerate scale-up and reduce the cost and time of facility commissioning. Fourth, pursue integrated partnership models where process development, clinical manufacturing, and regulatory support are closely coordinated to maintain continuity and accountability across transitions. This approach reduces knowledge loss during tech transfer and improves overall program velocity. Finally, commit to workforce development and cross-functional training to ensure teams can execute complex programs end-to-end, combining technical proficiency with regulatory and quality-system literacy to maintain compliance under evolving regulatory expectations.

Practical and reproducible research approach combining interviews, technical literature, and regulatory guidance to validate operational and strategic manufacturing insights

This research synthesis draws on a multi-channel analysis of primary and secondary inputs to create a coherent view of manufacturing trends, operational challenges, and strategic responses within cell and gene therapy biomanufacturing. Primary inputs include structured interviews with senior manufacturing, CMC, and regulatory leaders across sponsor and service-provider organizations, supplemented by technical dialogues with process development scientists and supply chain managers to understand operational constraints and mitigation strategies. These qualitative engagements were designed to surface real-world decision criteria and to reconcile differences between clinical development imperatives and commercial manufacturing requirements.

Secondary inputs comprised peer-reviewed literature, regulatory guidances, technical white papers, and public disclosures from product developers and service providers to validate technology trends and facility design patterns. Cross-validation techniques were used to triangulate insights from interviews with documented process architectures and regulatory expectations. Attention was paid to reproducibility of technical claims, and areas of high uncertainty are explicitly noted where divergent industry practices remain. The combined approach emphasizes practical relevance, privileging insights that can inform near-term operational planning and strategic partnerships while documenting assumptions and limitations that readers should consider when applying findings to specific programs.

Concluding synthesis that links manufacturing strategy, regulatory readiness, and supply chain resilience as the core determinants of long-term success for advanced therapies

Synthesis of the technical, operational, and strategic threads reveals a manufacturing ecosystem in transition: scientific innovation is accelerating therapeutic possibilities, but realizing those possibilities reliably requires focused investments in process science, supply chain resilience, and integrated partnerships. Organizations that harmonize early-stage development with scalable manufacturing practices, diversify sourcing and regional exposure, and commit to robust analytics and quality systems will be better positioned to sustain program momentum and patient access as therapies move toward broader clinical adoption.

Looking ahead, the interplay of technology choices, regulatory expectations, and commercial realities will continue to shape which programs can be advanced sustainably. Stakeholders that view manufacturing strategy as an enabler of clinical and commercial success-rather than a downstream constraint-will capture disproportionate value. The challenge is to translate technical ingenuity into reproducible, regulatory-ready processes at scale, and the most successful organizations will be those that build integrated roadmaps linking process development, regulatory planning, and supply chain design to deliver therapies reliably to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Clinical Manufacturing
  • 8.3. Commercial Manufacturing
  • 8.4. Process Development

9. Cell & Gene Therapy Biomanufacturing CDMO Market, by Therapy Type

  • 9.1. Cell Therapy
    • 9.1.1. Allogeneic
    • 9.1.2. Autologous
  • 9.2. Gene Therapy

10. Cell & Gene Therapy Biomanufacturing CDMO Market, by Technology

  • 10.1. Non-Viral Vector
    • 10.1.1. Electroporation
    • 10.1.2. Lipid Nanoparticles
  • 10.2. Viral Vector
    • 10.2.1. Aav
    • 10.2.2. Adenovirus
    • 10.2.3. Lentivirus
    • 10.2.4. Retrovirus

11. Cell & Gene Therapy Biomanufacturing CDMO Market, by Scale

  • 11.1. Clinical Scale
  • 11.2. Commercial Scale
  • 11.3. Preclinical Scale

12. Cell & Gene Therapy Biomanufacturing CDMO Market, by Process Stage

  • 12.1. Downstream
  • 12.2. Upstream

13. Cell & Gene Therapy Biomanufacturing CDMO Market, by Application

  • 13.1. Cardiovascular
  • 13.2. Neurology
  • 13.3. Oncology
  • 13.4. Rare Diseases

14. Cell & Gene Therapy Biomanufacturing CDMO Market, by End User

  • 14.1. Biopharmaceutical Companies
  • 14.2. Contract Research Organizations
  • 14.3. Research Institutions

15. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Cell & Gene Therapy Biomanufacturing CDMO Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Cell & Gene Therapy Biomanufacturing CDMO Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Cell & Gene Therapy Biomanufacturing CDMO Market

19. China Cell & Gene Therapy Biomanufacturing CDMO Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AGC Biologics, Inc.
  • 20.6. Ajinomoto Bio-Pharma Services, Inc.
  • 20.7. Alvotech A/S
  • 20.8. BioNTech SE
  • 20.9. BioReliance
  • 20.10. Catalent, Inc.
  • 20.11. Charles River Laboratories International, Inc.
  • 20.12. Cobra Biologics Holdings Ltd.
  • 20.13. Cobra Therapeutics
  • 20.14. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • 20.15. Genezen Laboratories, Inc.
  • 20.16. Lonza Group AG
  • 20.17. Merck KGaA
  • 20.18. Minaris Regenerative Medicine GmbH
  • 20.19. Novasep SAS
  • 20.20. Paragon Bioservices, Inc.
  • 20.21. Recipharm AB
  • 20.22. Rentschler Biopharma SE
  • 20.23. Repligen Corporation
  • 20.24. Samsung Biologics Co., Ltd.
  • 20.25. Thermo Fisher Scientific, Inc.
  • 20.26. Thermo Genesis Holdings, Inc.
  • 20.27. Vironova AB
  • 20.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)